Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1607 + Ipilimumab + Pembrolizumab in Advanced Melanoma
NCT06784648Phase 2Active, not recruiting
- Sponsor
- BioInvent International
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of BI-1607 in melanoma, sponsored by BioInvent International. Started Dec 2024; status: active, not recruiting.
02
Drugs
BI-1607
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06784648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784648.